Search results | biomarkers


Sorry, your search returned no results.


Biomarkers: recent life science industry trends

Recent advances in biomarkers, pharmacogenomics, bioinformatics and companion diagnostics have raised opportunities in the emerging field of personalized medicine

InterMune looking for oppurtunities for buyout

Multiple sources are reporting that biotechnology company, InterMune, Inc. (ITMN), is officially preparing for a buyout.

Personalized medicine

Personalized medicine proposes customization of healthcare – with medical decisions, practices, and/or…


Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by…


A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use

Q1 Life Science Partnering Trends in 2014

Smaller biotech deal making pips smaller pharma to the Q1 post by signing 300 deals, which is over half the amount made in the whole quarter

Personalized medicine: recent life science partnering trends

Recent advances in biomarkers, pharmacogenomics, and companion diagnostics have increased partnering trends and opportunities in the emerging field of personalized medicine.

Ipsen: Developing niche products to increase life expectancy

Ipsen is a French specialty pharmaceutical company developing products to increase life expectancy.

Personalized medicine in oncology: recent life science partnering trends

Scientists predict that the cure to cancer in the future lies in exploiting personalized medicine technology.

Cardiovascular partnering – recent deal analysis 2007-2013

Partnering deal analysis in the last decade has seen an increase in cardiovascular partnering with an increase in modern diagnostic technologies


Sorry, your search returned no results.


Banyan Biomarkers signs pharma licensing deal with Abbott

Banyan Biomarkers has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott for assessment and verification . The terms of the in a pharma licensing agreement were not disclosed.

Qiagen and Eli Lilly sign a biotech deal for biomarkers

QIAGEN announced a collaboration on a biotech deal with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.

KineMed biopharma partners with Amgen for kinetic biomarkers

KineMed biopharma partners with Amgen, a big pharma company, to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases

Joslin pharma partnering with Eli Lilly and Pfizer for biomarkers

Joslin Diabetes Center’s Office of Commercialization and Ventures is pharma partnering with Eli Lilly and Company and Pfizer which will enable Joslin and both companies to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes and developing potential ways to treat and prevent this complication of diabetes

Biogen Idec big pharma deals Adaptive Biotechnologies for immunological biomarkers collaborative R&D

Adaptive Biotechnologies signed pharma deals with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases.

BMS pharma deals for oncology biomarkers in collaborative R&D with Adaptive biotechnologies

Bristol-Myers Squibb has entered into a collaborative R&D pharma deals agreement with Adaptive biotechnologies  for the discovery of immunological biomarkers in oncology.

Astrazeneca pharma partners with Oxford Cancer Biomarkers

Big pharma company, AstraZeneca, has signed a deal to become pharma partners with Oxford Cancer Biomarkers to develop and personalize a cancer drug.

Merck Serono & Compugen establish a pharma alliances joint venture focussed on biomarkers

Merck Serono, a big pharma company has announced a joint venture pharma alliances collaboration with  Compugen to utilize its predictive discovery technologies for work focused on bio markers

ExonHit enters into research agreement with Pfizer to identify Alzheimer’s disease biomarkers

Research agreement with Pfizer for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform.

GNS Healthcare collaborates with BMS on novel disease biomarkers

GNS Healthcare has announced it has entered into a collaboration with Bristol-Myers Squibb focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.